The secret role of microRNAs in cancer stem cell development and potential therapy: a Notch-pathway approach

Marianna Prokopi, Christina A. Kousparou, Agamemnon A. Epeneto

MicroRNAs (miRNAs) have been implicated in the development of some if not all cancer types and have been identified as attractive targets for prognosis, diagnosis, and therapy of the disease. miRNAs are a class of small non-coding RNAs (20–22 nt in length) that bind imperfectly to the 3′-untranslated region of target mRNA regulating gene expression. Averently expressed miRNAs in cancer, sometimes known as oncomiRNAs, have been shown to play a major role in oncogenesis, metastasis, and drug resistance. Amplification of oncomiRNAs during cancer development correlates with the silencing of tumor suppressor genes; on the other hand, down-regulation of miRNAs has also been observed in cancer and cancer stem cells (CSCs). In both cases, miRNA regulation is inversely correlated with cancer progression. Growing evidence indicates that miRNAs are also involved in the metastatic process by either suppressing or promoting metastasis-related genes leading to the reduction or activation of cancer cell migration and invasion processes. In particular, circulating miRNAs (vesicle-encapsulated or non-encapsulated) have significant effects on tumorigenesis: membrane-particles, apoptotic bodies, and exosomes have been described as providers of a cell-to-cell communication system transporting oncogenic miRNAs from tumors to neighboring cells and distant metastatic sites. It is hypothesized that miRNAs control cancer development in a traditional manner, by regulating signaling pathways and factors. In addition, recent developments indicate a non-conventional mechanism of cancer regulation by stem cell reprogramming via a regulatory network consisting of miRNAs and Wnt/β-catenin, Notch, and Hedgehog signaling pathways, all of which are involved in controlling stem cell functions of CSCs. In this review, we focus on the role of miRNAs in the Notch-pathway and how they regulate CSC self-renewal, differentiation, and tumorigenesis by direct/indirect targeting of the Notch-pathway.

Keywords: Notch signaling, cancer stem cells, microRNAs, cancer therapeutics, miRNA therapeutics

BACKGROUND

Cancer is a heterogeneous disease with cellular hierarchies and many different phenotypes. Strong evidence points to the fact that the majority of cells in solid tumors are of non-tumorigenic origin. A small population of progenitor cells is thought to be responsible for tumor initiation, growth, metastasis, drug resistance, and recurrence. These cells are known as cancer stem cells (CSCs), since they possess stem cell characteristics such as self-renewal, asymmetric cell division, differentiation, and chemoresistance (1, 2). CSCs act via signaling pathways that mediate self-renewal, including Notch and Wnt. It is becoming widely accepted that irregular stem cell self-renewal is essential for cancer initiation, formation, and relapse and that CSCs play a central role in cancer cell biology. Thus the identification of specific markers of CSCs may be important in the discovery and development of novel oncology therapeutics.

NOTCH SIGNALING PATHWAY

The authors support the hypothesis that cancer initiation and development involve the improper activation of developmental signaling pathways. Normally such pathways control the growth of tissues and organs by maintaining the balance between cell proliferation, differentiation, senescence, and apoptosis. Notch signaling pathway plays a key role in stem cell self-renewal, cell proliferation, and differentiation. Consequently, it has important developmental functions, and its aberrant activation leads to many diseases and cancers (3–5). Notch genes encode large single pass transmembrane proteins that regulate cell fate determination (6). Previous studies in Drosophila, Caenorhabditis elegans, and mammalian cell cultures have shown that Notch act as receptors for the DSL (Delta, Serrate, and Lag-2) family of ligands and signal through two downstream pathways. One of these is via the CSL (CBF1, Suppressor of Hairless, Lag-1) family of transcription factors and the other via...
the cytoplasmic adapter protein Deltex. In mammals, the Notch signaling pathway includes four receptors (Notch 1–4) and five ligands (Delta-like 1, 3, and 4 & Jagged-1 and 2) (7). Notch signaling is initiated through ligand–receptor binding between two neighboring cells. Upon activation, Notch undergoes cleavage, releasing its intracellular domain NICD and translocates into the nucleus for transcriptional activation of its downstream target genes (8).

**NOTCH IN TUMORIGENESIS MEDITATED BY CSCs**

Modifications in the Notch-pathway and its associated genes can result in ligand dysregulation having dramatic developmental effects in humans, thus implicating Notch signaling in several inherited diseases such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infaracts and Leukoencephalopa-thy, Alagille syndrome, and Spondylocostal dysostosis. Since the discovery of Notch1 gene alterations in T-cell acute lymphoblastic leukemia/lymphoma, deregulated Notch signaling has been connected to many solid tumor pathologies and different cancer types (leukemia, neuroblastomas, skin, cervical, lung, prostate, and breast cancer) (4, 9, 10). The role of Notch signaling in tumorigenesis is thought to be mainly oncogenic, although some observations have suggested an anti-proliferative role in a small number of cancers (hepatocellular carcinoma and skin cancer) (11–13). The oncogenic function of Notch signaling is associated with high levels of Jagged-1, mainly in prostate and breast cancer, as well as with loss of Numb activity – a negative regulator of Notch-pathway – in 40% of breast cancers and 30% of lung cancers (5, 14, 15). Thus, the deregulation of the Notch signaling pathway has so far been linked to metastasis, recurrence, and reduced overall survival. On the other hand, tumor aggressiveness has been linked to the cross-talk between Notch and other oncogenic pathways such as Wnt/β-catenin, NF-kB, Ras, and Akt (16–18).

Although irregular activation of a single pathway may result in tumorigenesis, oncogenic pathways rarely operate in isolation. Cross-talk between signaling pathways adds to the complexity of the disease and are heavily influenced by the microenvironment. Recent studies have revealed that the interaction between the Notch and Wnt/β-catenin signaling pathways drives the CSC uncontrolled self-renewal, resulting in CSC-related tumor recurrence after treatment (19, 20). Notch signaling regulates both the CSC formation and the epithelial-to-mesenchymal-transition (EMT) phenotype during tumor progression. The EMT process, which occurs during tumor progression, drives the CSCs to become metastatic. Indeed, Notch-mediated EMT converts polarized epithelial cells into motile, invasive cells due to loss of E-cadherin – a membrane glycoprotein involved in the adherence of adjacent cells – which results in β-catenin activation and dissemination of cancer cells and CSCs from the primary tumor (21–23). Notch signaling pathway interacts with several oncogenic pathways, transcription, and growth factors (e.g., Snail, Slug, and TGF-β) regulating various biological and pathologic processes during cancer development, progression, and therapy. However, a growing body of evidence indicates that Notch is regulated at molecular level via cross-talk with miRNAs suggesting a critical role for these molecules in tumor biology (24, 25).

**MI RNA BIOGENESIS**

miRNAs are a class of small, non-coding RNAs that regulate mRNA by acting at the post-translational level (26). The interaction between miRNAs and mRNAs is highly complex; in particular each miRNA can control hundreds of gene targets underlining the extraordinary impact of miRNA on protein expression. We are just beginning to understand how this novel class of regulators affects processes, at least, in mammals. Processed from longer primary transcripts by Drosha and Dicer, miRNAs bind through imperfect complementarity to their target genes at the seed sequence (eight-base long), of the 3’ non-coding region leading to degradation of target mRNA due to deadenylation/mRNA cleavage or repression of mRNA translation initiation (27, 28). MiRNAs have been implicated in a wide range of cell functions – normal or pathological – comprising of cell proliferation, apoptosis, differentiation, and self-renewal (2, 29). Therefore, dysregulation of miRNAs is linked to a range of human pathologies including cancer and its expression is associated with cancer development, progression, and prognosis mainly because of their involvement in cell proliferation and apoptosis (30). MiRNAs were shown to be differentially expressed in cancer forming unique miRNA patterns with some miRNAs to have oncogenic activity while others have tumor suppressor activity (oncosuppressors). Thus, oncogenic miRNAs are upregulated in cancer whereas tumor suppressor miRNAs are downregulated (31). With regards to cancer biology, miRNAs targeting oncogenes are often located in fragile regions with a tension to be downregulated in tumors leading to overexpression of their target oncogenes. A breakthrough study showed that 50% of the annotated human miRNAs are positioned in these unstable sites and are associated with cancer and function in tumor progression (32).

**CANCER AND miRNAs**

Tissue-specific/tissue-enriched miRNAs, often deregulated, play a major role in cancer progress functioning as both oncosuppressors and oncogenes. For example, upregulated miR-21 is associated with breast and lung cancer, glioblastoma, leukemia, neuroblastoma, and liver metastasis (33, 34). Brain-specific neuromiR-124 is downregulated in glioblastoma resulting in increased CSC numbers and oncogenic capacity (35). On the other hand, let-7, normally expressed in lung, is downregulated in lung cancer and associated with poor survival (36), lung-specific pneumomiR-29 suppresses tumorigenicity in non-small cell lung cancer cells and miR-143 and miR-145 have been shown to be downregulated in breast, cervical, and colorectal cancers (37, 38). Moreover, loss of miR-15 and miR-16 has been related to chronic lymphoid leukemia by negatively regulating the anti-apoptotic gene BCL2, supporting a role in the immune system (39, 40). Similarly, many other miRNAs have been related to Notch signaling pathway, by regulating Notch-associated genes and affecting many types of cancer (Table 1).

**IMPORTANT miRNAs CONTROLLING CANCER VIA REGULATION OF NOTCH SIGNALING PATHWAY**

**MiR-34 FAMILY**

MiR-34 family is composed of miR-34a, miR-34b, and miR-34c and has been connected to the regulation of p53 and Notch
Table 1 | Important miRNAs regulating Notch signaling pathway and Notch-associated genes.

| miRNA | Cancer type/ cell | Notch-related target |
|-------|-------------------|----------------------|
| miR-34 family | Pancreatic CSCs | Bcl-2/Notch (42, 48) |
| miR-34a | Pancreas, melanoma, lung, breast, and glioma | p53/Notch1/Notch2/Jagged-1/Hes-1 (24, 57) |
| miR-34a | Prostate and colon CSCs | Notch1 (47, 59) |
| miR-34b/c | Melanoma and glioma | Notch1/Notch2 (45, 59) |
| miR-34c-3p | Glioma | Notch2 (45) |
| miR-200 family | Prostate | Jagged-1/Notch (49) |
| miR-200 | Squamous esophageal | ZEB-1/Notch3 (51) |
| miR-200b | Pancreatic cancer cell line | Jagged-1/2, Hes-1, Heg2, Bcl-2 (50) |
| miR-200c | Pancreatic adenocarcinoma | ZEB-1/Notch (Jagged-1, Maml2, Maml3) (48) |
| miR-199-5p | Medulloblastoma and osteosarcoma | Notch1/Jagged-1/Hes-1/Dll-1 (25) |
| miR-146a | Breast | Notch/Numb (53) |
| miR-1 | Colorectal | NOTCH3 (59) |
| miR-143 | Gliomus tumors | NOTCH1-3 (56) |

Signaling pathway. Low levels or no expression of miR-34 corresponds to higher probability of breast, brain, pancreatic, and non-small cell lung cancer suggesting a tumor suppressor role (24, 41, 42). Repression of miR-34a was identified in a panel of tumor-derived cancer cell lines such as pancreas, melanoma, lung, breast, and glioma (43, 44). However, miR-34b/c have been identified in derived cancer cell lines such as pancreas, melanoma, lung, breast, and glioma (43, 44). The involvement of miR-34 family has now been shown to affect major properties of CSCs. For example, it has been revealed that repression of miR-34 inhibits CD44+/CD133+ pancreatic CSCs self-renewal capacity through direct down-regulation of Bcl-2 and Notch signaling pathways (46). Furthermore, transfection with miR-34c-3p in U251 and U87 glioblastoma cell lines inhibited cell proliferation, induced cell apoptosis, and obstructed glioma cell invasion. Therefore, it was established that miR-34c-3p overexpression reduced the levels of Notch 2 (Figure 1) indicating that cell proliferation inhibition occurred via the Notch signaling pathway (45). On the other hand, it is well recognized that Notch 1 is linked to CSCs “stemness” characteristics and promotes the EMT phenotype, which is closely linked to many types of metastatic cancer. In prostate cancer for instance, upregulated levels of Notch 1 are highly associated with prostate cancer development, metastasis, and progression. Re-expression of miR-34a in C4-2B and CWR22rv1 prostate cancer cells reduced the expression of Notch1, decreased the self-renewal capacity and inhibited the growth of prostate cancer cells (47). Taken together, miR-34 family directs the regulation of Notch 1 and 2 protein expression in glioma cells, pancreatic, and prostate cancer cells mediating the suppression of self-renewal and differentiation properties of CSCs. Restoration of miR-34 levels could be eventually used as cancer therapeutic by down-regulating the Notch family members.

**MiR-200 FAMILY**

MiR-200 family consists of five members: miR-200a, miR-200b, miR-200c, miR-141, and miR-429. Recent studies have shown that the miR-200 family is highly implicated in the regulation of CSCs with examples involving breast, colorectal, prostate, and brain CSCs. Low levels of miR-200c and miR-141 are correlated with high expression of ZEB-1 – an EMT activator – which in turn activates Notch signaling pathway by targeting the Notch ligands and Notch co-activators Maml 2 and 3. Reduced expression of miR-141 and miR-200c affects stem cell properties and drug resistance in two human cancer types: pancreatic adenocarcinoma and basal type of breast cancer (48). Moreover, re-expression of miR-200 family including miR-141 and miR-429 directly inhibits Jagged-1 in human metastatic prostate cancer cells suggesting a new way to control the fate of Notch-pathway (49). Similarly, in another study transfection of miR-200b in Rink-1 cells (pancreatic cell line) have reduced the levels of Jagged-1/2 and these of their target genes Hes-1, Hey-2 (Figure 1), and Bcl-2 leading to cell growth inhibition (50). Another critical study connects NOTCH3 in the regulation of ZEBs and the miR-200 family revealing how critical is Notch in EMT, invasion and tumor formation in squamous esophageal cancers (51). However, more in-depth investigation is required in order to understand how the miR-200 family regulates the Notch signaling pathway.

**MiR-199 FAMILY**

MiR-199-5p has been linked to the transcription factor Hes-1 in medulloblastoma tumors where it regulates cell growth and several CSC genes via Notch signaling pathway. In metastatic cancer patients’ miR-199-5p expression is lost, yet re-expression of it blocks the Notch signaling pathway (Figure 1) and the population of medulloblastoma stem cell like cells is decreased (25). Zollo’s group went a step further by developing stable nucleic and lipid particles (SNALPs) to deliver miR-199-5p in different tumorigenic cell lines such as colon, breast, glioblastoma, and medulloblastoma. Impairment of cell proliferation and CSC-associated markers was due to effect of miR-199-5p delivery via SNALPs however, different efficacies due to cell type cannot be excluded and the efficiency of these carriers can be limited by their instability and non-specific targeting in vivo (52).

**SINGLE miRNAs REGULATING NOTCH**

Recently, miR-146a was also found to interact with Notch via regulation of Numb in breast carcinomas (53) and to stimulate NF-kB activity through Notch 1 [reviewed in Ref. (54)]. Another miRNA involved in Notch-pathway is miR-8, which it was reported that directly regulates Notch via Dll-1 protein in mouse embryonic stem cells. MiR-1 has been linked to human hepatocellular carcinoma, lung, prostate, and head and neck cancers; therefore it is only a matter of time for Notch to be associated with the above through miR-1 [reviewed in Ref. (54)]. A recent study by Furukawa (55) demonstrated the association of miR-1 in colorectal tumors and the potential to suppress NOTCH3 expression.
which in turn results in reduction of Asef regulating the growth, migration, and invasion potential of cancer cells. Other reports, show an association of MIR143 gene with NOTCH1-3; suggesting that the mechanism of MIR143–NOTCH1-3 tumorigenesis is through oncogenic activation of NOTCH driven by the very strong MIR143 promoter in malignant glomus tumors (56).

THERAPEUTIC APPLICATIONS OF miRNAs IN CANCER

The development of therapies against cancer and CSCs has driven toward a new generation of cancer therapeutics. RNA-based approaches promise to be one of the next major classes of cancer therapeutics. Advancements in genetics relating to the role of RNA in an ever-expanding range of cellular pathways and processes have shown that RNA has many of the genetic and regulatory properties formerly attributed only to DNA and proteins. Current work is based on modified mRNA regulating the expression of therapeutic proteins and on RNAi variants such as siRNA and miRNA, which can either block oncogenes or amplify oncosuppressor genes in cancer cells. The success of RNAi therapeutics hinges on their effective and safe delivery to their molecular targets inside cancer cells and tumors. However, targeted delivery remains a major challenge in miRNA therapy because naked ribonucleic acids are subject to rapid degradation by serum nucleases and miRNAs cannot diffuse freely into cells. To deliver the new class of targeted drugs, several technologies are under development including nanocapsules and nanocarriers, micro/nanoparticles, liposomes, and PEGylated vesicles. Delivery of miRNAs or miRNA inhibitors requires a flexible and efficient delivery system, for example, miR-34a has being encapsulated in stable-acid-lipid particles used to target Dll-1 in vitro (52). Other delivery approaches involve the use of agents such as polyethylenimine (PU-PEI) to mediate miRNA delivery. PU-PEI-mediated miR-145 delivery vehicle has been used successfully for miR-145 delivery to glioblastoma cells (60). Another candidate for the successful miRNA therapeutic approach is the vector-mediated overexpression of miRNAs to tumor tissues in vivo using adenoviral or lentiviral delivery. Of note, miR-26a expression in normal liver and liver tumor cells succeeded via adenoviral delivery in order to inhibit tumor cell proliferation and to lead in apoptosis (61). However, the use of this approach can only be employed in systemic local delivery. As the early clinical trial failures in the field have demonstrated, delivery of RNAi therapeutics to their molecular targets inside cancer cells is crucial. The authors have developed a novel system for miRNA delivery applicable for both local and systemic administration with the use of mesenchymal stem cell (MSC)-derived microparticles (MPs). The idea was based on the fact that miRNAs are released in the blood-stream via a controlled and active process through MPs, exosomes, and apoptotic bodies. MiRNAs associated with cellular particles were found to be resistant from nuclease degradation and able to be transferred in a variety of cells and alter the gene expression of the recipient cells (62–64). The novel technology designs for MSC-derived MPs programed to enclose and deliver specific miRNAs that affect the action of genes associated with cancer growth, neo-vascularization, and metastasis (65). MSC-derived MPs retain the membrane receptors that allow MSCs to home selectively into tumor sites and target malignant cells, thus avoiding the targeting of healthy cells. MSC-derived MPs home and engraft in solid tumors via specific chemokine receptors, fuse to tumor cell membranes, and incorporate miRNA directly into the target cancer cell, thus exerting their therapeutic effect while minimizing side effects associated with conventional therapies (65, 66). MSC-derived MPs offer enhanced therapeutic potential due to their ability to target multiple molecules in malignant cells when compared with approaches targeting single genes and induce immunosuppression through cytokine signaling inhibition making this approach useful in therapy of recurring cancer disease (65, 67).

CONCLUDING REMARKS

As miRNA expression seems to be altered in many human diseases, including cancer, the miRNA revolution has already begun and has set the stage for “miRNA re-expression therapy.” Among the many genes that miRNAs can regulate are oncogenes and tumor suppressors, targets of drugs currently used in the clinic. Although a few miRNAs are overexpressed in cancer and seem to function as oncogenes themselves, a greater number of miRNAs have been shown to be downregulated in cancer and have
the potential to act as tumor suppressors. miRNA re-expression and down-regulation have both been shown to have antitumor effects while re-expressing a tumor suppressor miRNA could downregulate multiple oncopgenes. Re-expression, to physiological levels, of tissue-specific miRNAs that are lost in cancer can induce the de-differentiation of cancer cells. Re-expressing lost miRNA in a cell can deliver a dramatic effect, because miRNAs regulate a vast number of genes and pathways. However, similar to other RNA-related therapies the key challenge remains the inadequate delivery and stability of the therapeutic agents to the tumor site. MiRNA antagonists and mimics are already available in the market but limited to local administration applicable to only a few target tissues. On the other hand, miRNA therapeutics could follow similar approaches to siRNA chemistry, vector-based systems as in gene therapy, and/or vehicle-based delivery systems. Understanding miRNA biology and how it contributes to cancer development it will provide for new diagnostic and therapeutic tools. MiRNA-based therapy is not a traditional approach and will need further development and improvements in composition, stability, and delivery to the target areas. Nevertheless, miRNA profiling will open a new era in cancer biology providing a new and improved cancer classification system.

REFERENCES

1. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol (2007) 23:675–99. doi:10.1146/annurev.cellbio.22.010305.104154
2. Colmont CS, Harding KG, Piguet V, Patel GK. Human skin cancer stem cells: a tale of mice and men. Exp Dermatol (2012) 21:576–80. doi:10.1111/j.1600-0625.2012.01533.x
3. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res (2006) 66:2778–84. doi:10.1158/0008-5472.CAN-05-4281
4. Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG, et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 19:1972–80. doi:10.1158/1078-0432.CCR-12-0570
5. Wang K, Wu X, Wang J, Huang C. Cancer stem cell theory: therapeutic implications for nanomedicine. Int J Nanomedicine (2013) 8:899–908. doi:10.2147/ijn.2013.03844
6. Wang Z, Banerjee S, Sarkar FH. Notch signalling in solid tumours: a little bit of everything but not all the time. Cell Cycle (2009) 8:1972–80. doi:10.4161/cc.8.17.8998
7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer (2004) 4:657–61. doi:10.1038/nrc1364
8. Di Leva G, Croce CM. miRNA profiling of cancer. Anticancer Res (2006) 26:225–32. doi:10.2147/ijon.2013.03844
9. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 137:216–33. doi:10.1016/j.cell.2009.03.045
10. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 11:338–51. doi:10.1038/nrc3035
11. Reynolds TC, Smith SD, Sklar J. Analysis of DNA surrounding the breakpoints of regions involved in cancers. Proc Natl Acad Sci U S A (2004) 101:2999–3004. doi:10.1073/pnas.0307323101
12. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol (2006) 24:4677–84. doi:10.1200/JCO.2005.35.5194
13. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther (2010) 10:1224–32. doi:10.4161/cbt.10.12.14252
14. Bivan S, Sun T. Functions of noncoding RNAs in neural development and neurological diseases. Mol Neurobiol (2011) 44:359–73. doi:10.1007/s12035-011-8211-3
15. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64:9584–7. doi:10.1158/0008-5472.CAN-04-2506
16. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 and JAGGED1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 110:726–36. doi:10.1002/jcb.22451
17. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64:9584–7. doi:10.1158/0008-5472.CAN-04-2506
18. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, et al. Down-regulation of Notch-1 and JAGGED1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem (2010) 110:726–36. doi:10.1002/jcb.22451
19. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64:9584–7. doi:10.1158/0008-5472.CAN-04-2506
20. Wang Z, Li Y, Banerjee S, Sarkar FH. Notch signalling in solid tumours: a little bit of everything but not all the time. Cell Cycle (2009) 8:1972–80. doi:10.4161/cc.8.17.8998
21. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions for nanomedicine. Int J Nanomedicine (2013) 8:999–908. doi:10.2147/ijn.2013.03844
22. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer (2011) 11:338–51. doi:10.1038/nrc3035
37. Hammond SM, RNAi, microRNAs, and human disease. Cancer Chemother Pharma-
col (2006) 58(Suppl 1):63–8. doi:10.1007/978-0-387-00318-2
38. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in
cancer. J Clin Invest (2009) 119:2119–23. doi:10.1172/JCI40107
39. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-
15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005)
102:13944–9. doi:10.1073/pnas.0506654102
40. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent
deletions and down-regulation of micro- RNA genes miR15 and miR16-1 at 13q14 in
chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 99:15524–9.
doi:10.1073/pnas.242606799
41. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA com-
ponent of the p53 tumour suppressor network. Nature (2007) 447:1130–4.
doi:10.1038/nature05939
42. Ts Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits
human pancreatic cancer tumor-initiating cells. PLoS One (2009) 4:e6816.
doi:10.1371/journal.pone.0006816
43. He C, Xiong J, Xu Z, Wu L, Liu L, Xiao D, et al. Functional elucidation of MiR-34
in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Com-
mun (2008) 388:35–40. doi:10.1016/j.bbrc.2008.07.101
44. Poellinger L, Lendahl U. Modulating Notch signaling by pathway-intrinsic
and pathway-extrinsic mechanisms. Curr Opin Genet Dev (2008) 18:149–54.
doi:10.1016/j.gde.2008.07.013
45. Wu Z, Wu Y, Tian Y, Sun X, Liu J, Ren H, et al. Differential effects of miR-34c-3p
and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells.
Oncol Lett (2013) 6:1447–52. doi:10.3892/ol.2013.1579
46. Wang X, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of
Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic
cancer cells. Mol Cancer Ther (2006) 5:483–93. doi:10.1158/1535-7163.MCT-
05-0299
47. Kashat M, Azzouz L, Sarkar SH, Kong D, Li Y, Sarkar FH. Inactivation of AR and
Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. Am J
Transl Res (2012) 4:432–42.
48. Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, et al. The
INK4a/Arf deficiency cooperate during the development of pancreatic cancer.
Cancer Res (2007) 67:8366–47. doi:10.1158/0008-5472.CAN-11-0846
49. de Antonellis P, Liguori L, Falanga A, Carotenuto M, Ferrucci V, Andolfi I,
et al. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles
(SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol (2013)
386:287–302. doi:10.1007/s00210-013-0837-4
50. Wang X, Lu H, Li T, Yu L, Liu G, Peng X, et al. Kruppel-like factor 8 promotes
tumorigenic mammary stem cell induction by targeting miR-146a. Am J Cancer
Res (2013) 3:536–73.
51. Wang Z, Li Y, Ahmad A, Arzmi AS, Banerjee S, Kong D, et al. Targeting Notch sig-
naling pathway to overcome drug resistance for cancer therapy. Biochem Biophys
Acta (2010) 1806:258–67. doi:10.1016/j.bbabio.2010.06.001
52. Fukurawa S, Kawasaki Y, Miyamoto M, Hiyoshi M, Kitayama J, Akiyama T. The
miR-1-NOTCH3-Asel pathway is important for colorectal tumor cell migration.
PLoS One (2013) 8:e68069. doi:10.1371/journal.pone.008609
53. Prokopi et al. miRNAs in Notching signaling pathway

Conflict of Interest Statement: The Guest Associate Editor Aleksandra Filipovic
declares that, despite having collaborated with author Agamemnon A. Epenetos,
the review process was handled objectively and no conflict of interest exists. The
authors declare that the research was conducted in the absence of any commercial
or financial relationships that could be construed as a potential conflict of interest.

Received: 07 November 2014; accepted: 31 December 2014; published online: 11
February 2015.
Citation: Prokopi M, Kousparou CA and Epenetos AA (2015) The secret role of microR-
NAs in cancer stem cell development and potential therapy: a Notch-pathway approach.
Front. Oncol. 4:389. doi: 10.3389/fonc.2014.00389
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of
the journal Frontiers in Oncology.
Copyright © 2015 Prokopi, Kousparou and Epenetos. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction
is permitted which does not comply with these terms.